Maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.
Molecular Imaging and Personalised Medicine
Molecular imaging (MI) is a type of medical imaging that provides unique insights into what is happening inside the body at the cellular and molecular level helping physicians to deliver “personalised medicine” – i.e. delivering the right treatment to the right patient at the right time, leading to better outcomes, improved quality of life and reduced costs. Unlike other medical imaging technologies such as x-rays, computed tomography (CT), magnetic resonance (MR) and ultrasound (US) which provide structural images, MI allows physicians to see how cells, tissues and organs are functioning and to measure chemical and biological processes without having to resort to biopsy or surgery.
MI procedures provide important information that help drive treatment decisions in patients with a range of conditions including cancer, infections, and disorders of the gastrointestinal, musculoskeletal and endocrine systems, kidney, heart, lung, and other organs.
Nuclear medicine (NM) is a form of MI in which images of the uptake of injected, inhaled or swallowed targeted radioactively-labelled tracers (radiopharmaceuticals) are captured with a gamma or SPECT camera.
For more information:
Society of Nuclear Medicine and Molecular Imaging: About Nuclear Medicine and Molecular Imaging